Cover Image
市場調查報告書

印尼的醫藥品·醫療產業(季度更新報告)

Indonesia Pharmaceuticals and Healthcare Report Q1 2017

出版商 BMI Research 商品編碼 177846
出版日期 內容資訊 英文 125 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
印尼的醫藥品·醫療產業(季度更新報告) Indonesia Pharmaceuticals and Healthcare Report Q1 2017
出版日期: 2016年11月09日 內容資訊: 英文 125 Pages
簡介

根據最新的報導指出,印尼府為了吸引海外的投資,打算取消包含醫藥品·生態旅遊·通訊的各種產業領域外資限制。但這個政策是否真的實施,以及何時實施都還沒有決定。同時外資企業也持續苦於印尼的高通貨膨脹率,這也成為(以美金為準)減收的要素。

本報告提供印尼的製藥·醫療產業結構和最新趨勢相關分析,提供今後10年的產業規模動向推計,彙整業界抱持的課題(風險)及未來性的收益機會(利潤)評估,政府的政策·規定,宏觀經濟環境,再加上主要企業簡介等資訊,為您概述為以下內容。

BMI的見解

SWOT分析

  • 政治
  • 經濟
  • 商務環境

產業預測

  • 醫藥品市場預測
  • 醫療市場預測
  • 處方藥市場預測
  • 專利藥市場預測
  • 學名藥市場預測
  • 一般用醫藥品(成藥)市場預測
  • 醫藥品的對外貿易情形
  • 醫療產業相關的其他資料
  • BMI的預測方案相關主要風險

宏觀經濟預測

  • 經濟分析
    • 一般收支的緩慢復甦
    • 受到三重苦的GDP

產業的風險/利潤·等級

  • 亞太地區:風險/利潤·等級
  • 印尼:風險/利潤·等級
    • 利潤
    • 風險

市場概況

產業的趨勢與發展

  • 流行病學
  • 非傳染病
  • 傳染病
  • HIV/AIDS
  • 公共衛生的發展
  • 醫療制度
  • 醫療保險
  • 醫療制度改革
  • 醫療觀光
  • 研究開發(R&D)
  • 臨床實驗
  • 生藥

法規的發展

  • 醫藥品的廣告
  • 跟域內標準的協調
  • 知識財產權相關課題
  • 清真醫藥品相關法規
  • 對標籤的要求標準
  • 強制許可證
  • 假藥
  • 學名藥相關的法律規章
  • 自由貿易協定(FTA)
  • 價格設定的體制
  • 醫療費給付的體制

競爭環境

  • 醫藥品產業
  • 國內產業
  • 外資產業
  • 製藥產業近年來的發展情形
  • 醫藥品的批發銷售
  • 醫藥品的零售

企業簡介

  • Soho Group
  • Darya-Varia Group
  • PT Kalbe Farma
  • PT Biofarma
  • Kimia Farma
  • Combiphar PT
  • Indopharma
  • Sanofi
  • Pfizer
  • Novartis
  • GlaxoSmithKline
  • Merck & Co
  • Bayer
  • Merck Group

人口結構的預測

  • 未來的人口結構預測

詞彙表

分析方法

  • 醫藥品支出額的預測模式
  • 醫療費的預測模式
  • 分析方法的相關註記
  • 風險/利潤·等級技術
  • 等級概要
  • 指標的加權

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1748-1945

BMI View:: Multinational pharmaceutical firms operating in Indonesia will continue to face a significant competitive threat from domestic companies. These firms are well established, with a presence across numerous sub-sectors including logistics, consumer healthcare and prescription drugs. Other firms, including government-owned Kimia Farma, have expanded into the provision of medical services, which will give them a distinct advantage in marketing its products. Moreover, generic drugs will remain the mainstay of the Indonesian medicine market. Indonesia's health insurance scheme will maintain this dominance through its mandate that patients be prescribed generic substitutes when possible.

Headline Expenditure Projections

  • Pharmaceuticals: IDR77.6trn (USD5.8bn) in 2015 to IDR85.6trn (USD6.4bn) in 2016; +10.2% growth in local currency terms and +10.9% in US dollar terms. Forecast held steady from previous quarter.
  • Healthcare: IDR330trn (USD24.7bn) in 2015 to IDR367trn (USD27.6bn) in 2016; +11.2% growth in local currency terms and +11.9% in US dollar terms. Forecast held steady from previous quarter.

Table of Contents

BMI Industry View

  • Table: Headline Pharmaceuticals & Healthcare Forecasts (Indonesia 2014-2020)

SWOT

  • Industry Forecast
  • Pharmaceutical Market Forecast
    • Table: Pharmaceutical Sales, Historical Data And Forecasts (Indonesia 2012-2020)
  • Healthcare Market Forecast
    • Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2012-2020)
    • Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2012-2020)
    • Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2012-2020)
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020)
  • Patented Drug Market Forecast
    • Table: Patented Drug Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020)
  • Generic Drug Market Forecast
    • Table: Generic Drug Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020)
  • OTC Medicine Market Forecast
    • Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020)
  • Pharmaceutical Trade Forecast
    • Table: Pharmaceutical Trade Data And Forecasts (Indonesia 2014-2020)
    • Table: Pharmaceutical Trade Data And Forecasts local currency (Indonesia 2014-2020)

Industry Risk/Reward Index

  • Asia Pacific Risk/Reward Index - Q1 2017
  • Indonesia Risk/Reward Index
    • Rewards
    • Risks

Regulatory Review

  • Intellectual Property Issues
  • Pricing Regime
  • Reimbursement Regime

Industry Trends And Developments

  • Market Overview
    • Table: UN Millennium Development Goals For Indonesia
  • Healthcare Sector
    • Table: Examples Of JKN Benefits
    • Table: Healthcare Resources (Indonesia 2010-2015)
    • Table: Healthcare Personnel (Indonesia 2010-2015)
    • Table: Healthcare Activity (Indonesia 2010-2015)
  • Research & Development
  • Clinical Trials
  • Epidemiology
    • Table: Estimated Number Of New Cases Of Cancer In Indonesia

Competitive Landscape

  • Research-Based Industry
    • Table: Selected List Of Pharmaceutical Business Areas With Restricted Conditions
    • Table: Multinational Market Activity
  • Generic Drugmakers
  • Pharmaceutical Distribution
  • Pharmaceutical Retail Sector

Company Profile

  • Bayer
  • Darya-Varia Group
  • GlaxoSmithKline
  • Indopharma
  • Kimia Farma
  • Merck & Co
  • Merck Group
  • Novartis
  • Pfizer
  • PT Biofarma
  • PT Kalbe Farma
  • Sanofi
  • Soho Group

Demographic Forecast

  • Demographic Outlook
    • Table: Population Headline Indicators (Indonesia 1990-2025)
    • Table: Key Population Ratios (Indonesia 1990-2025)
    • Table: Urban/Rural Population & Life Expectancy (Indonesia 1990-2025)
    • Table: Population By Age Group (Indonesia 1990-2025)
    • Table: Population By Age Group % (Indonesia 1990-2025)

Glossary

Methodology

  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
  • Index Overview
    • Table: Pharmaceutical Risk/Reward Index Indicators
  • Indicator Weightings
Back to Top